Abstract: Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.

Abstract: The invention provides compounds of formula (I) or a salt thereof, radiolabelled versions thereof, and their use in the diagnosis or in vivo imaging of Amyloid-associated diseases such as Alzheimer's disease

Abstract: The invention relates to compositions comprising acyl derivatives of 2?-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced biological damage, and methods for improving wound healing and tissue repair, comprising administering the compositions of the present invention to an animal.

Abstract: The invention relates to compositions comprising acyl derivatives of 2'-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced biological damage, and methods for improving wound healing and tissue repair, comprising administering the compositions of the present invention to an animal.

Abstract: A method and pharmaceutical for protecting against mutational damage in mammalian cells, irrespective of the nature of the mutagenic event or source of radiational or chemical insult or the like.

Abstract: There is disclosed an agent for preventing the adhesion of thallium 201 to a container which comprises a reducing substance as an active ingredient. There is also disclosed a radioactive diagnostic agent wherein the adhesion of thallium 201 to a container is prevented which comprises thallium 201 and a reducing substance.

Abstract: This invention relates to an application of riluzole or its pharmaceutically acceptable salts in the preparation of drugs having radiorestoring properties.

Abstract: A specialized derivative of fructose in which the compound is a fructose ester complexed with .beta.-cyclodextrin. Preferably, the fructose derivative is fructosehexanoate .beta.-cyclodextrin complex, and more preferably the fructose derivative is fructose-1-O-hexanoate .beta.-cyclodextrin complex. Fructose pentanoate and fructose heptanoate .beta.-cyclodextrin complexes are also included within the scope of the invention, and the fructose ester and the .beta.-cyclodextrin must be combined in approximately molar equivalent amounts. The present invention also includes a method for treating animals and humans with the instant fructose derivatives, to protect against tissue damage caused by doxorubicin cytotoxicity (particularly doxorubicin-induced cardiomyopathy or mucositis), ischemia, radiation damage and other sources of free oxygen radical cellular damage to the tissue of living animals and humans.

Abstract: Taurine analogues are used for scavenging active oxygen compounds and preventing and minimizing damage to the skin from ultraviolet rays. The taurine analogues have the following formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification.

Abstract: A liquid mixture for internal use for prophylactic health protection is based on the active ingredients of biological natural products and is used in particular for prophylactic protection against the negative consequences of the effects of radiation, such as x-rays and the like, on the human organism. The liquid mixture includes a mixture of cellular liquid brewer's yeast and juice from foods, as well as a neutral liquid diluting the mixture.

Abstract: Novel methods for prophylaxis and treatment of tissue damage resulting from cell membrane permeabilization are disclosed. Compositions comprising a surface active copolymer are employed to prevent permeabilization or to promote membrane repair. Methods for enhancement of cell survival following membrane permeabilization in vitro are also disclosed, along with methods for increasing the efficacy of transfection of cells with foreign exogenous macromolecules, in particular DNA, also involving treatment of permeabilized cells with a surface active copolymer. Also disclosed are novel methods for prophylaxis and treatment of tissue damage, and for enhancement of cell survival and transfection efficacy, using a surface active copolymer in combination with high energy phosphate compounds which are capable of recharging cellular energy stores and thereby potentiating cell repair and survival.

Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.

Abstract: A method of decreasing the toxicity of chemical therapeutic agents administered in cancer chemotherapy including adminstration to a patient undergoing chemotherapy. This reduction in toxicity can be accomplished by administering an effective amount of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate. Methods of inducing mucolytic activity and reducing toxicity of acetominophen overdose are also discussed. Such activities are induced through the administration of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate.

Abstract: Methods for providing radioprotection to humans and other animals employing certain organic derivatives of tellurium and selenium are disclosed.

Abstract: The invention relates to an environment-protective agent consisting of silicon-containing minerals for adsorbing radiactive metal isotopes and toxic heavy metals, which comprises as silicon-containing minerals with a particle size of 0.001 to 0.5 mm; a natural diatomaceous earth and at least two natural zeolite minerals of the general formulaM.sub.x O.Al.sub.2 O.sub.3.YSiO.sub.2.7H.sub.2 OwhereinM stands for sodium, potassium or calcium;x is a number between 1 and 2 inclusive of both extreme values;Y is 3 or 10; andZ is 6 or 7treated by dilute acid, washed to neutral, dried to a constant weight at a temperature up to 115.degree.0 C. and then heat-treated at 150.degree. to 350.degree. C., preferably at 250.degree. C., where the amount of each mineral ingredient independently of each other is at least 0.1% by weight up to 99.8% by weight calculated to the total weight of the agent.

Abstract: A composition and method for the treatment of inflammation, rheumatism, autoimmune disease, ischemic damage of organs, drug toxicity and arteriosclerosis comprising human ADF is disclosed.

Abstract: An antioxidative biophylactic agent containing a substance that can induce metallothionein production in human or animal body. Manganese or compounds thereof, Streptococcus hemolyticus which has been deprived of a streptolysin-S-yielding ability, and an extract from coriolus versicolor belonging to the family Polyporaceae, Basidomycetes having a remarkable metallothinonein-inducing ability in vivo, and an antioxidative biophylactic effect such as radiation damage protection can be obtained by administering these metallothionein-inducing substances.

Abstract: Skin treatment compositions are provided which inhibit generation of free radicals in the skin and which include 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 6-ethoxy-1,2-dihydro-2,3,4-trimethyl quinoline or mixture thereof, and optionally a stabilizer for the 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid which is monoethanolamine sulfite or sodium bisulfite.

Abstract: This invention provides method of preventing mucositis in a subject susceptible to mucositis comprising administering to the subject a prophylactically effective amount of granulocyte colony stimulating factor or a polypeptide analog thereof having substantially the same amino acid sequence and the activity of naturally occurring granulocyte colony stimulating factor. This invention further provides a method of treating mucositis in a subject having mucositis comprising administering to the subject a therapeutically effective amount of granulocyte colony stimulating factor or a polypeptide analog thereof having substantially the same amino acid sequence and the activity of naturally occurring granulocyte colony stimulating factor.

Abstract: Halogenated pyrimidine nucleoside derivatives with improved aqueous solubility and methods of enhancing the concentration of drugs in malignant tumors and promoting uniform distribution of the drug throughout the tumor. These basic and hydrophilic ester prodrugs are designed to undergo conversion to the active drug by an intramolecular chemical reaction at practical rates under physiological conditions.

Abstract: Skin treatment compositions are provided which inhibit generation of free radicals in the skin and which include 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 6-ethoxy-1,2-dihydro-2,2,4-trimethyl quinoline or mixture thereof, and optionally a stabilizer for the 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid which is monoethanolamine sulfite or sodium bisulfite.

Abstract: The present invention is directed to a method of inhibiting to onset of septicemia and endotoxemia. The methods comprise administering to a warm-blooded animal an effective amount of a pharmaceutical composition comprising Monophosphoryl lipid A in combination with a pharmaceutically acceptable carrier.

Abstract: A method for producing a product capable of adsorbing mutagen involving providing a fiber-rich, vegetable material capable of adsorbing mutagen by separating fibers from a vegetable, boiling the fibers and then washing and dewatering the fibers, prior to treating the fibers to produce dehydrated, fiber-rich vegetable material in particulate form by subjecting the fiber-rich material to a dehydration technique which preferably involves co-drying the fibers with carrier materials, and an ingestible product including fiber-rich vegetable material made from cabbage, radish, bamboo sprout, onion, carrot, pimiento, spinach, soybean malt, and asparagus.

Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycoalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group, and one of the groups represented byR.sup.2,R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl - C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group;and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage of radiological examination procedures.

Abstract: Skin treatment compositions are provided which inhibit generation of free radicals in the skin and which include 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 6-ethoxy-1,2-dihydro-2,2,4-trimethyl quinoline or mixture thereof.

Abstract: Use of 2,3-dimercaptopropane-1-sulfonic acid and/or 2,3-dimercaptosuccinic acid as well as their salts for combatting radiation injuries and poisonings effected by alkylating agents.

Abstract: There is disclosed a process for treating a warm-blooded animal to be subjected to radiotherapy or chemotherapy wherein there is administered to the warm-blooded animal a therapeutically effective amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzene) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.

Abstract: The present invention is directed to a method of inhibiting the onset of acute radiation syndrome caused by the exposure of warm-blooded animals to a whole body dose of at least about 100 rads of x-radiation. The invention is also directed to a method of inhibiting the onset of septicemia. The methods comprise administering to a warm-blooded animal an effective amount of a pharmaceutical composition comprising refined detoxified endotoxin in combination with a pharmaceutically acceptable carrier.

Abstract: The invention is directed to a synergistic radiation protective pharmaceutical composition comprising 50 to 350 parts by weight of aminoalkyl-thiol-derivatives of the general formula II ##STR1## wherein R.sup.3 stands for hydrogen, or carboxamidinoR.sup.4 stands for hydrogen or carboxy,B represents hydrogen or carboxamidino with the restriction that at least two of R.sup.3, R.sup.4 and B stand for hydrogen--or a pharmaceutically acceptable acid addition salt thereof, 0.2 to 2 parts by weight of .omega.-acylamino-alkane-derivative of the general formula ##STR2## wherein R.sup.1 stands for hydrogen, C.sub.1-4 alkanoyl, aroyl or aryl-(C.sub.1-4)-alkoxy-carbonyl,R.sup.2 stands for hydrogen, or carboxy optionally esterified by C.sub.1-4 alkoxy or aryl-(C.sub.1-4)alkoxy,A stands for --SO.sub.2 OH or --O--PO(OH).sub.2,n stands for 1, 2 or 3 andm stands for 2, 3 or 4--or a pharmaceutically acceptable salt thereof,and pharmaceutically acceptable carriers, diluents and/or solvents, and/or other formulating excipients.